Why the study?
Does colchicine prevent early atrial fibrillation events in patients undergoing cardiac procedures?
Does colchicine prevent early atrial fibrillation events in patients undergoing cardiac procedures?
Colchicine significantly reduces the risk of early atrial fibrillation following cardiac surgery compared to placebo.
Answers are grounded in this paper and cite their sources.
Supports colchicine for early AF prevention after cardiac procedures; confirms benefit in meta-analysis of trials.
OBJECTIVES: Inflammation is one of the predictors of atrial fibrillation (AF) following surgical or interventional cardiac procedures. Recent evidence suggests that colchicine may represent a new strategy to prevent AF following cardiac procedures. This study aims to assess the antiinflammatory efficacy of colchicine in prevention of early AF event (EAFE). MATERIALS AND METHODS: We reviewed all available studies that assessed the effectiveness of colchicine therapy on the occurrence of AF in patients undergoing cardiac procedures. Meta-analysis was performed by random effect inverse variance-weighted method by entering AF events and the total population from each study. RESULTS: After thorough review of the databases, we found three studies comparing colchicine and placebo which had EAFE as the outcome. Of 584 patients, 286 patients were on colchicine and 298 on placebo. All the three studies were randomized. After pooled analysis, colchicine was associated with significant reduction in AF events compared to placebo (odds ratio = 0.44 [0.29, 0.66], P < 0.001). There was no statistical heterogeneity between included studies (χ(2) = 0.45, P = 0.80, I(2) = 0%). CONCLUSION: Colchicine may prove beneficial in the prevention of AF following cardiac surgery. Further research is warranted.
No takes yet. Share an insight, caveat, or question.
Sadadia et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: